Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A

Trial Profile

An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Factor VIII stimulants
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms Kids A-LONG; Kids ALONG
  • Sponsors Biogen
  • Most Recent Events

    • 10 May 2019 According to a Swedish Orphan Biovitrum media release, final pooled post-hoc analysis data from A-LONG, Kids A-LONG and ASPIRE studies will be presented at the World Federation of Hemophilia's 16th International Musculoskeletal Congress (MSK).
    • 24 Apr 2019 According to a Swedish Orphan Biovitrum media release, long term safety and efficay data was presented at the European Association of Haemophilia and Allied Disorders (EAHAD) conference.
    • 07 Feb 2019 According to a Swedish Orphan Biovitrum media release, final longitudinal analysis of A-LONG/Kids A-LONG and ASPIRE will be presented at the European Association of Haemophilia and Allied Disorders (EAHAD) conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top